Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scandion Oncology announces that the results of the 4 SCO-101 clinical phase I trials have been published in the journal “Basic & Clinical Pharmacology & Toxocology”.

Scandion Oncology A/S (“Scandion Oncology”) announces that the results from the 4 SCO-101 phase I clinical trials have been published in the International peer-reviewed journal” Basic & Clinical Pharmacology & Toxicology”.“An important part of drug development is to publish the results from the different development phases in order to allow a more detailed evaluation of the development. I am very happy that we can now present the data from the 4 clinical phase I studies that were performed by the former owner of SCO-101. As previously announced, SCO-101

Selvaag Bolig ASA: Purchase of treasury shares

Selvaag Bolig ASA purchased 21 330 treasury shares on 10 July 2020. The shares were purchased at an average price of price of NOK 54.0933. The shares were purchased for the company's share programmes for employees. After the transaction, Selvaag Bolig owns 484 745 treasury shares.   Further information fromSverre Molvik, CFO, Selvaag Bolig ASATelephone: +47 401 00 585, e-mail: smo@selvaagbolig.no  Selvaag Bolig ASA is a residential property developer which controls the entire value chain from acquisition of land to sale of turnkey homes. The company has several thousand

Bambuser continues US growth – enters into agreement with fashion discovery platform Moda Operandi

Bambuser AB continues to grow in the US market with yet another new multi-brand retailer in the luxury segment. Today, Bambuser has entered into an agreement with Moda Operandi, one of the world's leading platforms for fashion discovery.   Moda Operandi (modaoperandi.com) is one of the world's leading platforms for designer fashion discovery. With an innovative mix of commerce and content, Moda Operandi offers more than 1,000 luxury brands and designers across fashion, fine jewelry and home, and ships to 125 countries. Bambuser has today signed a new agreement with Moda

Primary insider disclosure

The following primary insiders (or their related parties as described below) have, as part of the company's incentive program, committed to acquire shares in Ocean Yield ASA (the "Company" or "Ocean Yield"): · Lars Solbakken, CEO of Ocean Yield ASA, has through his wholly owned company Finmarine AS acquired 50,000 shares in Ocean Yield. Upon completion of such acquisition, Lars Solbakken will own, directly or indirectly, 1,640,880 shares in the Company. ·  Marius Magelie, SVP Finance & Investor Relations, has through his wholly owned company MGM Invest AS committed to acquire 7,500

Simris rights issue was oversubscribed

Simris (FNSE: SIMRIS) has concluded its rights issue of units which was announced on 12 June 2020. The subscription rate was circa 101.6 percent in total, of which circa 61.2 percent was subscribed with unit rights and circa 40.4 percent without unit rights. Consequently, underwriting commitments will not be called on. Simris receives circa SEK 29.1 million before transaction costs from the rights issue, of which circa SEK 2.2 million will be funded through offset of debt.IMPORTANT INFORMATION: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO AUSTRALA, HONGKONG,

BioStock: Aptahem comments on the new Covid-19 project

Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the University Health Network in Toronto. The collaboration will be anchored in Aptahem’s previously indicative positive preclinical data, and the objective is to evaluate whether the company’s drug candidate Apta-1 can show a positive treatment effect on the Acute Respiratory Distress Syndrome that can affect severe cases of Covid-19. BioStock contacted Aptahem’s CSO Dr Luiza Jedlina for a comment.Read the full interview at biostock.se: https://www.biostock.se/en/aptahem-comments-on-the-new-

Flowscape wins new orders in Australia

One of Flowscapes global customers is expanding their installations in Australia with a new office in Brisbane and a complementing order for their Sydney office. The Flowscape solution will be an important part for a safe return to the offices after the Covid-19 lock down. The order value is 1.3 MSEK first year and thereafter SEK 300,000 annually."Over the past month, we have seen a great interest from several countries for our new Covid-19 solution for safe social distancing at the office. With this order, our system will be used in two large offices in Australia with a total of over 1000

Vator Securities: CREATE Health delivers another exciting tech, ProMIS, which potentially could open up a world of new IP for Immunovia

In our latest research update on Immunovia (link to report ), we presented our forecast of a future diagnostic regimen including a combination of proteomics and genomics-based techs to generate timely and correct diagnosis of cancer. Published in the impactful Nature Communication Biology, (link to article ), Immunovia’s research arm and collaborator CREATE Health demonstrates the powerful combination of the two techs in its novel academic research project, the ProMIS platform. The

Storytel acquires the Nordic audiobook production company Earselect

Storytel AB (publ) (“Storytel”), Northern Europe’s leading audiobook and e-book streaming service, is acquiring an 80 percent majority interest in Earselect AB, a Nordic production company offering a dynamic, flexible and scalable cloud based platform specialised in remote audiobook production.With Storytel AB as new majority owner, Earselect’s efficient technology for both traditional production and a remote workflow, will support Storytel’s production line, and also continue to provide high quality and cost-efficient productions to external publishers with full business integrity as

AGENT study update with regards to COVID-19

GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the outbreak of COVID-19 has affected the general situation of the AGENT study activities. Patient recruitment has been ongoing without interruption during the pandemic, but the effects of COVID-19 may result in a delay of the full enrolment by up to three months.As hospitals, regions and countries have updated their guidelines, Isofol has adapted accordingly to be fully compliant with the new procedures. In order to ensure continuity of the ongoing AGENT study in a

Sold Out Signs Two New Titles

Today, EG7 announces that the subsidiary Sold Out has signed publishing agreements regarding two new titles. The signed publisher agreements concern developer ColePowered Games' upcoming sci-fi title Shadows of Doubt as well as an as a yet unannounced title from Auroch Digital. The two titles join Sold Out's fast-growing portfolio of digital titles. More information will be communicated in the coming months. Comment from Robin Flodin, CEO of EG7: “We are pleased that Sold Out has signed agreements with both ColePowered Games and Auroch Digital, two very talented developers that

Invitation to presentation of Handicares interim report January-June 2020

On the 17[th ]of July at 08.00 AM (CET), Handicare will publish its interim report for January-June 2020. At 09.00 AM (CET) the same day, the company holds a conference call, where President and CEO Johan Ek presents the report together with CFO Pernilla Lindén. After the presentation follows a Q&A session. The conference call will be held in English. The interim report and a presentation will be available on the website, www.handicaregroup.com. After the conclusion of the conference call, there will be a recording on the website. To participate in the conference, please register on the

MPC Container Ships ASA announces allocation of shares to primary insiders

Oslo, 10 July 2020 – Reference is made to the stock exchange announcement made by MPC Container Ships ASA ("MPCC" or the "Company") on 10 July 2020 regarding the successful completion of a private placement with gross proceeds of NOK 260,000,000 by issuance of 260,000,000 new shares at a subscription price of NOK 1.00 per share (the "Private Placement"). The Private Placement was fully underwritten by existing shareholders and primary insiders in the Company: STAR Spike Ltd. (a fund managed by STAR Capital Partnership LLP) ("STAR"), CSI Beteiligungsgesellschaft mbH and associated parties

Magnolia Bostad sells 230 residential units in Partille

Magnolia Bostad has sold residential units in the new Partille Port district to Heimstaden Bostad. Around 230 residential units are planned in the property of 12,500 m[2] GFA as well as 3,000 m[2  ]GFA of retail units and an underground garage. The estimated property value upon completion is around SEK 560 million.The sale will be a corporate transaction and refers to the Partille 11:61 property, which is located in Partille Port, a new urban development project just east of Göteborg. The project is part of the framework agreement signed with Heimstaden in June 2018. There is a zoning plan

Vestas expands its multibrand fleet in Europe with service agreement for Senvion turbines in Croatia

News release from Vestas Northern and Central EuropeHamburg, 10 July 2020 Leveraging industry-leading multibrand service capabilities, Vestas has secured a service agreement for the Croatian wind energy project Orjak in northern Croatia from VJETROELEKTRANA ORJAK d.o.o., a daughter company of ECOwind Handels-und Wartungs-GmbH, which is a subsidiary of global renewable energy developer BayWa r.e.     Vestas will deliver the maintenance of the project’s five Senvion MM92-2.05 wind turbines and the 18-year Active Output Management 4000 (AOM 4000) service agreement will commence

BioStock: Abliva’s KL1333 development plan receives OK from FDA

As Abliva prepares for its next steps in the clinical development of KL1333, the company has received good news from FDA. At a pre-Investigational New Drug meeting, FDA presented positive feedback to Abliva’s plans for continuation with the project aimed at developing a new treatment of primary mitochondrial diseases.Read the full article at biostock.se: https://www.biostock.se/en/ablivas-kl1333-development-plan-receives-ok-from-fda/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

ITAB publishes EBITDA guidance for the financial year 2020 and its mid-term profitability ambition and announces the intention to carry out a capital raise to strengthen ITAB’s financial position

As a result of the evolving situation with Covid-19 and the consequent impact on our customers, ITAB has decided to provide preliminary EBITDA guidance for the financial year ending 31 December 2020, which is subject to change given the evolving situation with Covid-19.ITAB currently expects EBITDA for the financial year ending 31 December 2020 to be in the range of 380 to 420 MSEK before non-recurring costs which amount to approximately 100 MSEK, primarily relating to operational restructuring costs. The total restructuring costs for the One ITAB transformation plan are estimated to be in

Interim Report January - June 2020

THE INTERIM PERIOD JANUARY - JUNE 2020 · Net sales decresed -18% to SEK 2,558 million (3,134) · Operating profit amounted to SEK 75 million (251) · Profit after financial items amounted to SEK 34 million (208) · Profit after tax amounted to SEK 22 million (156) · Earnings per share amounted to SEK 0.23 (0.52) · Cash flow from operating activities amounted to SEK 383 million (223) In 2020, non-recurring items impacted the profit after financial items bySEK -42 million (75).   APRIL - JUNE 2020 · Net sales decresed -25% to SEK 1,142 million (1,531) ·

Bambusers enters into an agreement with Aim’n regarding Live Video Shopping

Bambuser AB has entered into an agreement with the Swedish activewear brand Aim’n. The agreement runs for six months and relates to a limited version of Live Video Shopping for retail. The company estimates that revenues will be lower in relation to previously entered into agreements for a full version. On 13 May 2020, Bambuser announced that the company will start offering a few selected companies different packaging to lower the threshold for small and medium-sized enterprises (SMEs) to enter into agreements for Live Video Shopping and in order to evaluate a varied pricing strategy

NPRO: Notice of extraordinary general meeting

Please find Notice of extraordinary general meeting in Norwegian Property ASA enclosed. The general meeting will be held on Monday 10 August 2020 at 0830 hours CET at Bryggegata 6 (5th floor) in Oslo, Norway. The notice will be sent to all shareholders and is also available at the company's website www.norwegianproperty.no.The board has decided to call an extraordinary general meeting to request authorization to increase the share capital by up to NOK 49,985,000 by subscription of new shares, equivalent to just below 20% of the current share capital. The power of attorney will be in

Period-end comment from Setra Q2 2020

Wood products company Setra is reporting an operating profit of SEK 59 million (117) for the first six months of 2020. Net sales totalled SEK 2,203 million (2,383). Operating profits for the second quarter amounted to SEK 47 million (34), with net sales totalling SEK 1,109 million (1,255).The effects of the COVID-19 virus continue to cause uncertainty. To date, however, Setra has succeeded in maintaining its full sawmill production, without furloughing any employees. Setra’s crisis management team is monitoring the development of the virus and its potential impact on Setra’s operations on

Vasakronan’s interim report January–June 2020

Strong lettings in the first six monthsDuring the period, renegotiations and lease extensions corresponded to 185,000 square metres (171,000) and annual rent of SEK 485 million (473), resulting in an increase on the previous rent payable of 8.3% (13.9). The Swedish Medical Products Agency has extended its lease at the Uppsala Science Park property for slightly more than 20,000 square metres for a period of six years and Försäkringskassan (the Swedish Social Insurance Agency) has signed a six-year extension to its lease at the Godset property in Sundbyberg for 7,300 square metres. ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top